Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.

Josephine F TrottOmran Abu AboudBridget McLaughlinKatie L AndersonJaime F ModianoKyoungmi KimKuang-Yu JenWilliam SenapedisHua ChangYosef LandesmanErkan BalogluRoberto PiliRobert H Weiss

Published in: Kidney360 (2022)

This study highlights the potential of the RENCA model for evaluating immunologic responses to KPT-9274 and checkpoint inhibitor (CPI) and suggests that therapy with this combination could improve efficacy in RCC beyond what is achievable with CPI alone.

Keyphrases

papillary thyroid
dna damage
cell cycle
squamous cell
squamous cell carcinoma
small molecule
mesenchymal stem cells
climate change